Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Chemotechnique Diagnostics is a world leader in the development and manufacture of high-quality patch test allergens (haptens) and diagnostic systems for contact allergy. Founded in 1981 and headquartered in Sweden, the company provides an extensive catalog of over 550 different haptens, as well as specialized patch test units like the IQ Ultra and IQ Ultimate. Their products are utilized by dermatologists and allergists globally to diagnose allergic contact dermatitis through controlled skin exposure testing. In addition to physical test components, the company develops specialized software solutions to streamline the patch testing and documentation process in clinical settings. Chemotechnique is recognized for its contributions to the International Contact Dermatitis Research Group (ICDRG) and its role in standardizing allergy testing protocols.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Chemotechnique Diagnostics.